Código QR (código de barras bidimensional)

Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic inflammatory diseases with overlapping features. Mepolizumab, a humanized mAb targeting IL-5, has been approved for treatment of both conditions. However, real-world data on its cl...

Fuld beskrivelse

Na minha lista:
Principais autores: Michael E. Wechsler, MD, Anna Kovalszki, MD, Brian Stone, MD, Jared Silver, MD, PhD, Lior Seluk, MD, Jeremiah Hwee, PhD, Lynn Huynh, MPH, MBA, DrPH, Wilson da Costa Junior, MD, PhD, Shuang Wang, PhD, Mei Sheng Duh, ScD, William McCann, MD, Amy G. Edgecomb, PharmD, MPH
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2026-07-01
Serier:Journal of Allergy and Clinical Immunology: Global
Fag:
Eosinophilic granulomatosis with polyangiitis
hypereosinophilic syndrome
mepolizumab
oral corticosteroids
clinical outcomes
end-organ manifestations
Online adgang:http://www.sciencedirect.com/science/article/pii/S2772829326000573
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker